The most important facilitators and barriers to the use of Health Technology Assessment in Canada: a best-worst scaling approach

Wieslawa Dominika Wranik, Ronaldo-Raul Szekely, Susanne Mayer, Mickael Hiligsmann*, Kei Long Cheung

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)846-856
Number of pages11
JournalJournal of Medical Economics
Volume24
Issue number1
DOIs
Publication statusPublished - 1 Jan 2021

Keywords

  • Health Technology Assessment
  • Canadian Pharmacare
  • selection of pharmaceuticals
  • best-worst scaling
  • relative importance scores
  • DECISION-MAKING PROCESSES
  • ECONOMIC-EVALUATION
  • PREFERENCES
  • HTA

Cite this